Agile Therapeutics Stock News

Here's what you need to know about trading penny stocks on April 13th The post Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes  appeared first on Penny Stocks to Buy, Picks, News and Info

Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information |

Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information |

PRINCETON, N.J., April 11, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the receipt of $4.7 million in net proceeds from the sale

Upgrades UBS upgraded the previous rating for First Republic Bank (NYSE:FRC) from Neutral to Buy. For the fourth quarter, First Republic Bank had an EPS of $2.02, compared to year-ago quarter EPS of $

The abstract was accepted by ACOG and will be presented from May 4th – May 6th, 2022 The abstract was accepted by ACOG and will be presented from May 4th – May 6th, 2022

Agile Therapeutics has finished its first full year as a commercial company and was able to establish an attractive growth curve for Twirla in several metrics.

Partners with Award-Winning Director Maya Albanese

AGRX earnings call for the period ending December 31, 2021.

Agile Therapeutics (AGRX) delivered earnings and revenue surprises of -17.65% and 3.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Twirla Demand Grows with Cycles Dispensed and Total Prescriptions (TRx) Up 35% and 33% Respectively in Fourth Quarter 2021 vs Third Quarter 2021

Agile Therapeutics, Inc.'s (AGRX) CEO Al Altomari on Q4 2021 Results - Earnings Call Transcript

Agile Therapeutics (AGRX) delivered earnings and revenue surprises of -17.65% and 3.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Agile Therapeutics (AGRX) is down ~6% pre-market after announcing a $4.85M equity offering.The women''s healthcare company entered into a securities purchase agreement with a…

In the last trading session, 1.51 million shares of the Agile Therapeutics Inc. (NASDAQ:AGRX) were traded, and its beta was 1.19. Most recently the company’s share price was $0.25, and it changed around $0.0 or 0.59% from the last close, which brings the market valuation of the company to $30.36M. AGRX currently trades at a … Agile Therapeutics Inc. (NASDAQ: AGRX) Could See Prices Soar In The Coming Months Read More »